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Summary We examined a panel of 25 small cell lung cancer (SCLC) cell lines and nude mouse xenografts for
expression of the proto-oncogenes c-met and c-kit, and for expression of the corresponding ligands, hepatocyte
growth factor (HGF) (also known as scatter factor (SF)), and stem cell factor (SCF), respectively. Expression
of mRNA was detected by Northern blotting, and c-met and c-kit protein expression was detected by Western
blotting and immunocytochemistry. c-met and c-kit mRNA was expressed in 22 of the examined cell lines or
xenografts, and coexpression of the two proto-oncogenes was observed in 20 tumours. Expression of c-met and
c-kit protein parallelled in the mRNA expression. HGF/SF mRNA was expressed in two of the examined
tumours, and only one of these also expressed the c-met proto-oncogene. SCF mRNA was expressed in 19 of
the examined tumours, and in 18 of these coexpression of c-kit and SCF was present. The high percentage of
SCLC tumours expressing c-met and c-kit indicates that these proto-oncogenes may have an important
function in this disease. The rare coexpression of c-met and HGF/SF is evidence that an autocrine regulatory
pathway is not present for this receptor/ligand system in SCLC, while the frequent coexpression of c-kit and
SCF indicates that this receptor/ligand system may have an autocrine function in SCLC.
Overexpression of proto-oncogenes is a common feature of
human cancer. Proto-oncogenes may be divided into a
number of groups according to their cellular functions. One
prominent group is the tyrosine kinase family of proto-
oncogenes (Cantley et al., 1991), a subgroup of which
encodes proteins which are cell surface receptors, and which
phosphorylate tyrosine residues on intracellular proteins
when an appropriate ligand is bound to the receptor. This
subgroup includes the c-met (Dean et al., 1985) and c-kit
(Yarden et al., 1987) genes, as well as other known proto-
oncogenes.
Recently, c-met was shown to be identical to the hepato-
cyte growth factor receptor (HGFR) (Bottaro et al., 1991;
Naldini et al., 1991a; Naldini et al., 1991b), which has
hepatocyte growth factor (HGF) (Nakamura et al., 1989;
Miyazawa et al., 1989; Nakamura, 1991) as one known
ligand; HGF is identical to the molecule known as scatter
factor (SF) (Naldini et al., 1991b; Weidner et al., 1991),
which is known to increase the motility of many cell types
including carcinoma cells (Stoker, 1989; Gherardi et al., 1989;
Weidner et al., 1990). HGF/SF has the ability to promote
growth of hepatocytes (Nakamura et al., 1989), inhibit
growth of certain tumour cells (Shiota et al., 1992; Tajima et
al., 1991), and increase motility of many cell types (Stoker,
1989; Gherardi et al., 1989; Weidner et al., 1990). These
diverse effects of HGF/SF could be of importance for the
behaviour of c-met/HGFR expressing SCLC cells.
The c-kit proto-oncogene has recently been identified as
the receptor for stem cell factor (SCF) (Zsebo et al., 1990;
Williams et al., 1990), alternatively termed mast cell growth
factor (Anderson et al., 1990) or hematopoietic growth factor
KL (Huang et al., 1990).
Examination of the level of expression of tyrosine kinase
growth factor receptors in tumour cells may be of particular
importance in instances where an appropriate ligand is
available to the tumours. In such cases the binding of the
ligand to the surface receptors on tumour cells may con-
tribute to the growth regulation of the cells. This could be in
an endocrine, paracrine or autocrine manner, depending on
the site of production of the ligand.
We examined the expression of c-met and c-kit mRNA and
protein in a panel of 25 SCLC cell lines and nude mouse
xenografts in order to determine if these genes are expressed
in SCLC. In addition, we examined the panel for expression
of HGF/SF and SCF which are known ligands for the c-met
and c-kit tyrosine kinase growth factor receptors, respec-
tively.
The panel of SCLC tumours included cell lines and nude
mouse xenografts established in five different laboratories in
Europe and USA, and is thus likely to be widely represen-
tative for this disease. Most tumours were propagated both
as cell lines and as xenografts in order to explore the possible
role of the growth conditions on the expression of the
examined proto-oncogenes and their ligands.
Both c-met and c-kit mRNA was expressed in the majority
of the examined SCLC cell lines and xenografts (together
referred to as 'tumours'), and expression of the correspon-
ding proteins was found to parallel the expression of their
mRNAs. Only two tumours expressed detectable amounts of
HGF/SF mRNA transcripts, and only one of these two also
expressed c-met mRNA. In contrast to this, several tumours
expressed both c-kit and SCF.
Our results are the first to demonstrate expression of c-met
and HGF/SF in SCLC, and the data presented also provide
the first demonstration of c-kit protein in this disease.
Materials and methods
Cell lines and xenografts
Twenty-five tumours established from 20 patients were inves-
tigated. Five tumours were grown only as xenografts, six
tumours only as cell lines, while the remaining 14 were
investigated both as cell lines and as xenografts.
Cell lines were grown at 37°C in a humidified atmosphere
containing 5% CO2. Media contained 10% foetal calf serum.
Tumours designated CPH were established in Copenhagen,
Denmark (Engelholm et al., 1986), DMS tumours at Dart-
mouth Medical School, NH, USA (Pettengill et al., 1980),
the NCI tumours at the National Cancer Institute, MD,
USA (Carney et al., 1985), and GLC tumours at University
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Hospital of Groningen, The Netherlands (de Leij et al., 1985;
Berendsen et al., 1988). CPH-54A and CPH-54BN are in
vitro established subclones of the same original tumour
(Engelholm et al., 1985), and CPH-136A and CPH-136B
were established from the same patient before and after
chemotherapy, respectively. GLC-14, GLC-16, and GLC-19
were established from the same patient during longitudinal
follow-up (Berendsen et al., 1988), the same was the case for
GLC-26 and GLC-28. The cell line MAR-24H was estab-
lished at Marburg, Germany (Bepler et al., 1987). Cell lines
were regularly tested and found free of Mycoplasma infec-
tion.
Cells for investigation were harvested in mid- to late
exponential growth phase. Harvesting was done by scraping
with a rubber policeman for cells growing attached to the
bottom of culture flasks, and by aspiration for cells growing
as floating aggregates. The cells were washed in sterile buffer
(150mM NaCI-10mM EDTA-10mM Tris-pH8.0), spun
down, immediately frozen in liquid nitrogen, and stored at
-80°C until further processing.
Xenografts were established in the flanks of nude mice by
s.c. inoculation of 106_ 10 cells from cell lines, or directly
from patients by inoculation of 2-mm-diameter tumour
blocks (Spang-Thomsen et al., 1980). Serial transplantation
was performed by s.c. inoculation of 2-mm-diameter tumour
blocks under general anaesthesia. The mice were of NMRI or
BALB/c origin and in specific pathogen-free status; they were
kept in laminar air-flow clean benches. Sterile food and water
were given ad libitum. Xenograft samples for investigation
were cut free from visible necrotic tissue, immediately frozen
in liquid nitrogen, and stored at - 80°C.
RNA extraction and Northern blotting
RNA was extracted by the acid guanidinium phenol chloro-
form method (Chomczynski & Sacchi, 1987), dissolved in
diethyl pyrocarbonate treated water, and the concentration
determined by spectrophotometry. Twelve gg total RNA
samples were electrophoresed through 1% agarose gels con-
taining 2.2 M formaldehyde (Sambrook et al., 1989), and
transferred to nylon membranes (GeneScreen Plus, NEN
DuPont) in 10 x SSC (saline sodium citrate: 1 x SSC is
150 mM sodium chloride - 15 mM sodium citrate).
Membranes were prehybridised at 42°C in 50% (v/v) for-
mamide - 1% (w/v) sodium dodecyl sulfate - 1 M sodium
chloride - 5% (w/v) dextran sulfate - 100ijgml-' salmon
testes DNA, and hybridised to denatured probes (see below)
for 18-20 h in the same hybridising buffer. Maximal washing
stringency was 63-65°C in 2 x SSC - 1% (w/v) sodium
dodecyl sulfate for 1 h. Membranes were exposed to X-ray
film for 1 to 7 days at - 80°C with an intensifying screen.
Studies of c-met, c-kit and HGF/SF expression in normal
adult human tissues were performed on 'Multiple Tissue
Northern Blots' (MTN Blots, Clontech, Palo Alto, CA).
These blots contain 2ytg poly A' RNA from adult human
heart, brain, placenta, lung, liver, skeletal muscle, kidney and
pancreas. All procedures with MTN Blots were performed
according to the manufacturers instructions.
Radio-labelled human cDNA probes were prepared by the
random priming method (Feinberg & Vogelstein, 1983) using
[a32P]-dCTP and a commerical kit (both from Amersham).
The c-met probes were a 1.3 kb EcoRI fragment of the
plasmid phosl (kindly provided by G.F. Vande Woude) or a
0.5 kb EcoRI fragment of the plasmid pmet5 obtained from
the American Type Culture Collection (ATCC) (Park et al.,
1987); the phosI c-met probe recognises both translocated
and untranslocated c-met as well as c-met transcripts of
different sizes (G.F. Vande Woude, personal communica-
tion), while the pmet5 probe recognises only a single untrans-
located human c-met transcript (Park et al., 1987). The
HGF/SF probe was a 0.7 kb MluI-SalI fragment of the
plasmid pKK233DEP5 (Nakamura et al., 1989), and the c-kit
probe was a 1.25 kb SstI fragment of the plasmid phckit-171
obtained from the ATCC (Yarden et al., 1987), the SCF
probe was a 0.46 kb SmaI-Hindlll fragment of the plasmid
pGEM3:hSCF.#9 (kindly provided by K. Zsebo (Zsebo et
al., 1990)) and the human P-actin probe was a 2.1 kb BamHI
fragment of the plasmid pHFPiA-l (Gunning et al., 1983).
Protein extraction, electrophoresis and c-met immunoblotting
Cell and tissue samples for protein extraction were homo-
genised in lysis buffer (25 mM Tris (pH 7.5) - 50 mM NaCl -
0.5% (w/v) sodium-deoxycholate - 1% (v/v) Nonidet P-40 -
0.1% (w/v) sodium dodecyl sulfate - 1 mM phenylmethyl-
sulfonyl fluoride - 500 KIE ml-' aprotinin (Trasylol, Bayer)),
further homogenised by ultrasonication, and centrifuged for
15 min at 12,000g. The supernatant was transferred to a new
tube and the protein concentration determined with a com-
mercial kit utilising bicinchoninic acid (Pierce, France). Sam-
ple buffer containing ,-mercaptoethanol was added to the
supernatant to give a final protein concentration of 2jgpl-1.
Samples containing 50 yg total protein were boiled for 5 min
and size-fractionated by electrophoresis through SDS con-
taining 7.5% polyacrylamide gels. Molecular weight markers
in the 42-200 kD range (Bio-Rad, CA) were coelectro-
phoresed. The electrophoretically separated proteins were
transferred to nitrocellulose membranes (0.45tim, Schleicher
& Schuell, Dassel, Switzerland) by semi-dry electroblotting
(Kyhse-Andersen, 1984) according to the manufacturers in-
structions (JKA, Copenhagen, Denmark).
Membranes were blocked for 1 h in 50 mM Tris (pH 7.4) -
150 mM NaCl - 0.1% Tween-20 - 4% Non-fat dry milk
(Carnation, USA) - 10 mM sodium azide. After three washes
in Tris buffered saline (TBS) the primary c-met specific
antibody, 19S, was added. This antibody is monoclonal and
raised in mouse against a 50 kD protein (pSOmet) from the
carboxy-terminal part of the human c-met protein. The
antibody was used as ascites fluid in a dilution of 1:1000 in
50 mM Tris (pH 7.4) - 150mM NaCl - 0.05% Tween-20 -
2% bovine serum albumin (BSA)- 10mM sodium azide;
incubation time was 3 h. Following three washes in TBS, a
secondary alkaline phosphatase coupled rabbit anti-mouse
antibody (Dakopatts, Glostrup, Denmark) was added in dilu-
tion 1:2000 for 1 h in buffer identical to that used for the
primary antibody. After washing, bound antibody was vis-
ualised by a chromogenic reaction catalysed by the con-
jugated alkaline phosphatase using nitroblue tetrazolium and
5-bromo-4-chloro-3-indolyl phosphate as chromogenic sub-
strate.
Controls included incubation without primary antibody
and incubation with primary antibody which had been prein-
cubated with the p50met protein which was used for immun-
ization (1 gg peptide per 1 l ascites fluid). Both these control
experiments completely eliminated binding to proteins with
Mr's equivalent to those of c-met specific bands (data not
shown). The c-met antibody and the corresponding blocking
protein, p5Omet, was a generous gift of Dr Marianne Oskars-
son, NCI-Frederick, USA. The available c-met specific anti-
body was not suitable for use in immunocytochemistry.
Western blotting and immunocytochemistry ofc-kit protein
expression
Western blotting was performed as described for c-met except
that the buffer used for blocking and incubation was 100 mM
Tris (pH 7.4) - 150 mM NaCl - 10% foetal calf serum - 2%
BSA - 0.1% Triton X-100. The antibody was a mouse
monoclonal (Boehringer Mannheim, Germany), and was
used at a concentration of 10pgml'. A blocking peptide
was not available for this antibody.
Immunocytochemistry was employed to determine the
localisation of c-kit protein in the SCLC cells. Cell lines
growing attached to the bottom of culture flasks were grown
on 8-well slide glasses until attached, while cells growing in
suspension culture were washed in phosphate buffered saline
(PBS), placed on 8-well slide glasses in a small amount of
PBS and allowed to dry completely. Cells on slide glasses
were fixed in 1% formaldehyde in PBS for 10 min, washed in
PBS and blocked with 10% foetal calf serum in PBS forC-MET, C-KIT, HGF/SF AND SCF IN SCLC 39
30min. After washing in PBS, a polyclonal c-kit specific
antibody was added at a concentration of Ojig ml 1 in PBS
containing 4% BSA, and incubated for 4 h at room temp-
erature. The primary antibody was raised in rabbits against a
peptide with the sequence GSTASSSQPLLVHDDV, repre-
senting amino acids 961-976 in the C-terminal part of c-kit
protein (Oncogene Science, Uniondale, NY). The specimens
were washed in PBS containing 0.1% Tween-20 and incu-
bated for 1 h with a FITC-conjugated swine anti-rabbit
antibody (Dakopatts, Glostrup, Denmark) diluted 1:20 in
PBS containing 4% BSA. An epifluorescence microscope
(Aristoplan, Leica) equipped with filters appropriate for
FITC fluorescence was used for viewing and photographing.
Controls included incubation without the primary antibody
and incubation with primary antibody which had been pre-
incubated with the peptide used for immunisation (Oncogene
Science). Preincubation was done with a 10-fold excess (by
weight) of peptide.
Results
The expression of mRNA transcripts of c-met, HGF/SF,
c-kit and SCF in SCLC cell lines and xenografts is sum-
marised in Table I. There was no systematical difference in
expression pattern in the two model systems. In most cases
there were similar expression levels in the two systems, but in
some cases expression was slightly higher in a cell line than in
the corresponding xenograft and vice versa.
Expression of c-met mRNA was detected in 22 of the 25
examined SCLC tumours (Figure 1). Most of the tumours
expressed a single transcript with an electrophoretic mobility
corresponding to a size of 7.5 kb. However, a few tumours
(e.g. CPH-167 and DMS-456) also expressed a mRNA of
about a 6 kb Figure 1), which was detectable only with the
phosl probe (see Materails and methods).
The protein encoded by c-met was expressed in tumours
expressing c-met mRNA (Figure 4), and in general the ex-
pression levels of c-met protein corresponded well with the
levels of c-met mRNA. On the Western blots two bands with
Mr's of 145,000 (pl45MET, (Giordano et al., 1989b)) and
170,000 (pl70ME) were observed in all positive tumours, the
p145MET band being most prominent. In a few tumours (e.g.
DMA-273 xeno and NCI-H69) the level of protein expression
was relatively high despite the fact that c-met mRNA was
quite low.
The level of c-met expression detected in different tumours
varied widely (Figure 1). In general, tumours expressing c-
met did so both when grown as cell lines and as nude mouse
xenografts. However, a few tumours (e.g. CPH-54A, CPH-
54B) expressed very low levels of c-met when grown in vitro
as cell lines, whereas no expression was detectable in the
corresponding xenografts.
Expression of c-met mRNA was also examined in normal
adult human tissues, and high levels were detected in pla-
centa and lung, while moderate expression was observed in
heart, brain, liver, skeletal muscle and kidney (Figure 3). In
pancreas, only trace levels of c-met expression was found.
In the examined SCLC tumours, expression of mRNA for
the c-met ligand, HGF/SF, was detectable only in DMS-114
and NCI-N417 (Figure 1). Expression of HGF/SF was deter-
mined in various normal adult human tissues (MTN Blot, see
Materials and methods), and expression was detected in heart,
placenta, lung, liver, muscle (weak) and kidney (Figure 3).
Expression of c-kit mRNA was demonstrated in 22/25
SCLC cell lines (Figure 2). As was the case for c-met, the
Table I Expression of c-met, HGF/SF, c-kit and SCF in SCLC cell lines and nude mouse xenografts and in normal adult human
tissues
c-met HGF/SF c-kit SCF
Tumour line xeno line xeno line xeno line xeno
CPH-54A (+) _ _ _ _ _ _ _
CPH-54B (+) _ _ _ _ _ _ _
CPH-136A NA + + NA - NA + + + NA +
CPH-136B NA + NA - NA + + + NA + +
CPH-167 NA (+) NA - NA + NA + +
CPH-186 NA + + NA - NA + NA +
CPH-187 NA + NA - NA + NA +
DMS-53 ++ + - - + (+) - -
DMS-79 +++ +++ - - +++ +++ + +
DMS-92 + (+) - - + + + + + + + +
DMS-114 - - + + ++ _ (+) (+)
DMS-153 + + + - _ + ++ + + +
DMS-273 + + + - - (+) - (+) -
DMS-406 - NA - NA + + NA + + NA
DMS-456 + + + + - - + + - -
GLC-2 - NA - NA + NA - NA
GLC-3 + + - - + + + + + +
GLC-14 + (+) _ - ++ + ++ +
GLC-16 + (+) - - ++ + +
GLC-19 ++ + _ - + + + ++ ++
GLC-26 + NA - NA + + NA + + + NA
GLC-28 + + NA - NA + + NA + + + NA
NCI-H69 (+) (+) - - + + + +
NCI-N417 + + NA + NA (+) NA (+) NA
MAR-24H + + NA - NA + NA (+) NA
Normal tissues
heart + + + +
brain + + + +
placenta ++ +++ + +
lung ++ ++ +++ ++
liver + + + (+) (+)
muscle + (+) +
kidney + + + + ++
pancreas
The level of expression was rated visually as none: '-', trace: '(+)', low: '+', intermediate '+ +', and high: ++ +'. Xenografts marked
'NA' were not established as cell lines and vice versa.a < m qcT CD -,
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Figure 1 Northern blots demonstrating expression of the c-met proto-oncogene and of HGF/SF in SCLC cell lines a, and
xenografts b. The two upper blots were probed with the phosl and the pmet5 probes, respectively. A 7.5 kb band was detected by
both c-met probes, and an additional c-met specific band of approximately 6 kb (arrow) was seen in some tumours on blots probed
with the phosl probe (top). The lower two blots demonstrate expression of a 6 kb HGF/SF transcript and of P-actin, respectively.
An asterisk in b, marks non-specific hybridisation to the 4.8 kb ribosomal RNA band. Each lane contains 12 jig total RNA. The
positions of the coelectrophoresed size markers or of the 18S (1.9 kb) and 28S (4.8 kb) ribosomal RNA bands are indicated.
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Figure 2 Northern blot demonstrating expression of the c-kit proto-oncogene and of SCF in SCLC cell lines a, and xenografts b.
The upper panel was probed with a c-kit specific probe, the middle panel with a SCF specific probe, and the bottom panel with a
P-actin specific probe. Each lane contains 12jig total RNA. The positions of the 18S (1.9 kb) and 28S (4.8 kb) ribosomal RNA
bands are indicated.
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expression of c-kit seemed independent of the model system
in which the tumours cells were grown. Coexpression of
c-met and c-kit mRNA was found in 20 tumours.
Western blotting of c-kit protein demonstrated that there
was very good correlation between the level of c-kit protein
expression and c-kit mRNA expression (Figures 2 and 5).
Two bands with Mrs and 145,000 and 120,000 were detected.
The Mr 145,000 band is the c-kit receptor while the Mr
120,000 band is most likely a precursor (Blume-Jensen et al.,
1991).
Immunocytochemical analysis of cell lines with and with-
out detectable expression of c-kit mRNA was also per-
formed. The examined tumours were the c-kit mRNA
positive DMS-92, DMS-153, DMS-273, DMS-406, GLC-14,
GLC-16, GLC-19 and NCI-H69, and the c-kit mRNA
negative CPH-54A, CPH-54B and DMS-114. In all tumours
expressing c-kit mRNA, clear cell-membrane staining was
observed together with some cytoplasmic staining with
nuclear shadowing (Figure 6). In cell lines in which c-kit
mRNA and protein were not detectable on Northern and
Western blots (e.g. CPH-54A and CPH-54B), very weak
membrane staining was detected. In all cases the staining
could be completely eliminated by preincubation of the
primary antibody with the peptide used for immunisation
(Figure 6) or by omission of the primary antibody.
The ligand for c-kit, SCF, was expressed in 19/25 tumours,
and coexpression of the c-kit receptor and its ligand was
found in 18 of the examined tumours.
Normal adult human tissues frequently expressed both
c-kit and SCF mRNA (Figure 3).
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Discussion
Twenty-two of 25 tumours (88%) expressed detectable a-
mounts of c-met mRNA transcripts and c-met protein.
Two bands were detected by the 19S c-met monoclonal
antibody on Western blots of proteins electrophoresed under
reducing conditions. The smaller band represents the c-met
P-chain (pl45MET) while the 170,000 band most likely repre-
sents uncleaved c-met precursor, p170MET (Giordano et al.,
1989a; Giordano et al., 1989b). The a-chain with a M, of
50,000 (p5OMEl), which is presumed to be derived from the
amino-terminal part of the p170MET precursor (Tempest et
al., 1988), is likely not to be detected by the 19S antibody
which was raised against a carboxyterminal c-met-protein
(p5Omet).
It has been suggested that the size (9 kb) often reported for
the c-met mRNA species expressed in various tissues (Park et
al., 1986; Park et al., 1987; Prat et al., 1991) is likely to be an
overestimate (Park et al., 1987). Examination of overlapping
human c-met cDNA clones and heteroduplex analysis with
full length mouse met cDNA, which is close to 7 kb long
(Iyer et al., 1990), indicated that the human c-met transcript
is likely to be of approximately the same size (Park et al.,
1987). In accordance, the two c-met specific probes (pmetS
and phosI) used in the present study both detected a band
with an electrophorectic mobility of 7.5 kb. One of the c-met
probes used, pmet5, is known to recognise only one band on
Northern blots (Park et al., 1987). Examination of several
Northern blots where an RNA size marker which included a
band of 7.46 kb was coelectrophoresed, and of MTN Blots
where the position of size marker bands are marked,
repeatedly showed a c-met specific band with an electro-
phoretic mobility of 7.5 kb (Figures 1 and 3). To ascertain
the authenticity of our pmet5 probe, we performed Southern
blotting of TaqI digested human DNA and obtained the
expected 3 bands (Dean et al., 1987) of approximately 1.8,
3.2 and 11.0 kb (data not shown). Our results is further
evidence that the actual size of the human c-met mRNA is
close to 7.5 kb.
A few tumours expressed an additional c-met specific
mRNA species with a size of approximately 6 kb detectable
with the phosI probe but not with the pmet5 probe. In some
tumours the phosl probe detects up to three different c-met
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Figure 3 Northern blots showing expression of c-met (top),
HGF/SF (upper middle), c-kit (lower middle), and SCF (bottom)
in normal adult human tissues (MTN Blot). Each lane contains
2,ig poly A' RNA. The positions of the coelectrophoresed size
marker bands are indicated.
specific transcripts reported to be 6, 7, and 9 kb (Park et al.,
1987), and a 5 kb transcript of a fusion gene resulting from
translocation of tpr (translocated promoter region) sequence
from chromosome 1 to c-met sequence on chromosome 7
(Park et al., 1986; Park et al., 1987). As judged from its size,
the 6 kb band is not likely to represent the 5 kb tpr-met
fusion transcript, but rather one of the two other c-met
transcripts of 6 and 7 kb. Thus, the examined SCLC tumours
expressed only one additional c-met transcript when probed
with the phosI probe, while other tumour cells have been
reported to express at least two transcripts smaller than the
7.5 kb transcript detected by both c-met probes (Park et al.,
1986; Park et al., 1987; Prat et al., 1991).
If the c-met protein detected in the examined SCLC
tumours encodes a functional receptor, this may be ofimpor-
tance for the behaviour of SCLC tumours in patients, since
the c-met ligand, HGF/SF, is expressed in many normal
tissues (Figure 3), and is present in the plasma (Nakamura et
al., 1989; Zarnegar et al., 1990). We detected HGF/SF ex-
pression in several normal tissues (Figure 3), thus confirming
that this growth factor is widely expressed (Rubin et al.,
1991; Higashio et al., 1990; Yanagita et al., 1992). However,C-MET, C-KIT, HGF/SF AND SCF IN SCLC 43
< m Lo C a) _ LA r% LO
4t Co CY) co co LA N- 07) V- r It
LI I (_)
i U) U)
cn U n U n ,6
EL L. CL CL E 2 E E 2 E
D 0 a D D
6
ci
LA
-J CD
a-c)
6
CD
c) (D
I
z
qt CV) XV CD CD Xl (0 CMro LA LA
LA N- Q) Ien N4 Co
I
cb C 0h ch h cA cn 6 L
0 0c] a a a a CD 0
a)
co a) co 0O to
-4 -4 -4 -4 0
CD C0 CD Z
Figure 4 Representative Western blots demonstrating c-met protein expression in SCLC xenografts (top) and cell lines (bottom).
The positions of the coelectrophoresed size markers are indicated (in kD). The two c-met specific bands (pI45MET and pl70MET) are
indicated by arrows.
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Figure 5 Representative Western blots demonstrating c-kit protein expression in SCLC cell lines. The positions of the coelec-
trophoresed size markers are indicated (in kD). The two c-kit specific bands with Mrs of 145,000 and 120,000 are indicated by
arrows.
among the examined SCLC tumours, only two expressed
HGF/SF (Figure 1), and coexpression of c-met and HGF/SF
was found in only one tumour (NCI-N417). Therefore the
results do not indicate that an autocrine regulatory loop
involving this receptor/ligand system is frequently active in
SCLC.
Several normal tissues coexpressed c-met and its ligand
HGF/SF, and c-kit and its ligand SCF (Figure 3). This
suggests that these receptor-ligand systems may play a role in
normal growth regulation in an autocrine or paracrine man-
ner. It may be speculated that the expression of HGF/SF and
SCF in many normal tissues could be of importance for the
ability of SCLC tumour cells to metastasise to these tissues,
or that HGF/SF or SCF produced in various organs might
reach the lungs or sites with metastatic tumour spread and
modulate the growth of c-met and c-kit positive SCLC
tumours in situ. It is not known whether these ligands
stimulate or inhibit SCLC growth; recent studies of various
tumour cell lines, not including SCLC, have shown that
HGF/SF may inhibit tumour cell growth (Tajima et al.,
1991; Shiota et al., 1992), despite the fact that HGF/SF is a
potent mitogen for hepatocytes (Nakamura et al., 1989).
The fact that normal lung tissue expresses c-met mRNA
does not necessarily imply that c-met is expressed in SCLC.
The SCLC progenitor cell has not been identified with cer-
tainty, and it may represent only a minority of the cells
present in normal lung tissue.
In one previous study (Prat et al., 1991), three SCLC
patient biopsies were examined for c-met protein expression
by immunohistochemistry and none was detected. We detec-
ted c-met protein in the vast majority of cultured SCLC
tumours. The cause of the apparent difference between our
results and the results of Prat et al. (1991) is not clear at
present, but it may be necessary to examine larger materials
in order to determine whether there is an actual difference
between c-met protein expression in SCLC patient biopsies
and in cell lines.
The results obtained for the c-kit proto-oncogene confirm
recent data demonstrating frequent expression of c-kit
mRNA in SCLC (Sekido et al., 1991). In our series 22/25
(88%) SCLC tumours expressed c-kit mRNA, which is in
agreement with previous findings (Sekido et al., 1991). Our
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Figure 6 Immunocytochemical demonstration ofc-kit protein expression in representative SCLC cell lines. Micrographs on the left
show results of incubation with c-kit antibody in a concentration of lOlgml-'. Identically prepared samples incubated with
primary antibody which had been pre-absorbed with blocking peptide are shown on the right. The cell lines shown are CPH-54A
(top), DMS-153 (upper middle), GLC-16 (lower middle), and NCI-H69 (bottom). In all cases, micrographs of cells incubated with
primary antibody which had or had not been preincubated with blocking peptide were exposed and reproduced under identical
conditions. Magnification: x 1000.
results add important information to these previous findings
by demonstrating that the c-kit mRNA is translated into
protein. Immunocytochemical detection of very low levels of
c-kit protein was possible in some of the cell lines in which
c-kit mRNA or protein could not be demonstrated by North-
ern or Western blotting. This is most likely due to the very
high sensitivity of immunocytochemical techniques. SCF
mRNA was found to be expressed in a large proportion of
SCLC, and coexpression of c-kit and its ligand SCF was
demonstrated to be very frequent in SCLC, confirming very
recent results (Hibi et al., 1991).
Apparently, SCF is widely expressed in normal human
tissues (Figure 3). The production of SCF by SCLC tumour
cells and normal tissues may provide SCLC cells expressing
the c-kit receptor with a growth advantage and may thus
contribute to their malignant phenotype, provided that the
receptor and its ligand are functional, and provided that a
growth-stimulatory or an otherwise advantageous response is
elicited in cells upon binding of SCF.
The proto-oncogenes c-met and c-kit can now be added to
the long list of proto-oncogenes which are expressed in
SCLC (Birrer & Minna, 1989; Miikelii et al., 1991). It could
be speculated that expression of some of these genes may be
a result of a general deregulation of transcription in cancer
cells, leading to expression of genes that may not have any
function in the tumour cells. However, there is evidence that
expression of proto-oncogenes in SCLC is not the result of a
non-specific general increase in transcription. For example,
some proto-oncogenes, e.g. the c-erbB-2 gene is not expressed
in the panel of tumours examined here (data not shown), and
neither in another examined panel of SCLC (Schneider et al.,
1989). We also examined our SCLC tumour panel for expres-
sion of human serum albumin, which can be presumed to be
of absolutely no importance for SCLC tumours, and found
no detectable transcripts (data not shown). Indirectly, the
type of data suggest that only genes which have a function in
the tumour cells are expressed.
The fact that expresion of c-met and c-kit is found in
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SCLC and in several normal tissues as reported by us and
others (Prat et al., 1991; Iyer et al., 1990) suggests that these
receptors may be involved in the regulation of cell behaviour
in several tissues other than liver and stem cells. Thus, the
designation HGFR and SCF receptor may not completely
describe the function of these genes.
Recently, the ligands for c-met and c-kit, HGF/SF and'
SCF, have been cloned and expressed (Nakamura et al.,
1989; Miyazawa et al., 1989; Zsebo et al., 1990; Anderson et
al., 1990; Huang et al., 1990), and it is possible to produce
them in pure form. The availability of the ligands enables
further studies of the function of the c-met and c-kit recep-
tors in SCLC. It is of great potential interest that HGF/SF
has been shown to modulate cell growth and motility (Naka-
mura et al., 1989; Shiota et al., 1992; Tajima et al., 1991;
Stoker, 1989; Gherardi et al., 1989; Weidner et al., 1990).
HGF/SF is produced in normal lung tissue (Rubin et al.,
1991; Higashio et al., 1990; Yanagita et al., 1992) and thus
may act on SCLC cells in the patient. We are currently
investigating the possible effects of HGF/SF on SCLC cells.
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